Company: VRCA
Filing Date: 2025-04-30
Form Type: DEFR14A
Source: 0001193125-25-105562
Chunk: 55

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-04-30
Form: DEFR14A
Chunk 55
---
 to certain of our named executive officers, as detailed below, on March 14, 2025:

| Name                 |     | Number Of Shares 
 Underlying       
 Option Grant     |     |         |     | Exercise Price 
 Per Share      |   |      |     | Vesting  
 Schedule |     |    |
|:---------------------|:----|:-----------------|:----|--------:|:----|:---------------|:--|-----:|:----|:---------|:----|---:|
| Jayson Rieger        |     |                  |     | 850,000 |     |                | $ | 0.89 |     |          |     | -1 |
| Christopher G. Hayes |     |                  |     | 250,000 |     |                | $ | 0.89 |     |          |     | -2 |

| (1) | 1/8th of the total shares subject to the option shall vest on September 14, 2025, and 1/48th of the total shares subject to the option shall vest each month thereafter on the same day of the month, subject to the officer’s service as of each such date. |

| (2) | 50% of the total shares subject to the option vest on March 14, 2026 and 50% of the total shares subject to the option vest on March 14, 2027, subject to the officer’s service as of each such date. |

For additional information about equity grants made historically to our named executive officers, please see “—Outstanding Equity Awards as of December 31, 2024” above. Employment Arrangements and Potential Payments upon Termination of Employment or Change in Control We have entered into employment agreements with each of our current named executive officers. Dr. Rieger We entered into an offer letter with Dr. Rieger, our President and Chief Executive Officer, in November 2024. Under the terms of the agreement, Dr. Rieger was initially entitled to receive an annual base salary of $300,000 and an annual bonus of up to 40% of his annual base salary based upon our Board of Directors’ assessment of Dr. Rieger’s performance and our attainment of targeted goals as set by the Board of Directors in their sole discretion. Dr. Rieger also entered into an employee confidential information, inventions, non-solicitationand non-competitionagreement with us.